Amova Asset Management Americas Inc. Cuts Stake in Recursion Pharmaceuticals, Inc. $RXRX

Amova Asset Management Americas Inc. trimmed its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 16.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 6,221,025 shares of the company’s stock after selling 1,244,833 shares during the quarter. Amova Asset Management Americas Inc.’s holdings in Recursion Pharmaceuticals were worth $25,382,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals during the 4th quarter valued at about $31,000. Sequoia Financial Advisors LLC purchased a new stake in Recursion Pharmaceuticals during the 4th quarter valued at about $41,000. Allworth Financial LP grew its position in Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after purchasing an additional 4,403 shares during the last quarter. IFP Advisors Inc grew its position in Recursion Pharmaceuticals by 81.5% during the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after purchasing an additional 4,650 shares during the last quarter. Finally, Ethos Financial Group LLC purchased a new stake in Recursion Pharmaceuticals during the 4th quarter valued at about $53,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Ben R. Taylor sold 7,956 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the transaction, the chief financial officer owned 1,180,318 shares in the company, valued at $4,001,278.02. This represents a 0.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total transaction of $110,400.00. Following the sale, the director owned 6,169,863 shares in the company, valued at approximately $22,705,095.84. The trade was a 0.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,930 shares of company stock worth $435,942 in the last quarter. Company insiders own 8.43% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Bank of America lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Morgan Stanley boosted their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $8.10.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $3.22 on Wednesday. The firm’s 50 day moving average price is $3.31 and its 200-day moving average price is $3.80. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.77 and a twelve month high of $7.18. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1.71 billion, a PE ratio of -2.68 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The firm had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $15.78 million. During the same quarter in the prior year, the business earned ($0.50) EPS. The business’s quarterly revenue was down 56.8% on a year-over-year basis. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.